PMID- 35232283
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20220504
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 14
IP  - 6
DP  - 2022 Apr
TI  - Dermatological adverse events associated with immune checkpoint inhibitor-based 
      combinations of anticancer therapies: a systematic review.
PG  - 489-503
LID - 10.2217/imt-2021-0244 [doi]
AB  - Aim: This paper presents the reported dermatological adverse events (AEs) 
      associated with approved combinations of immunotherapy with drugs of the same 
      class, or in combination with targeted therapy or chemotherapy. Materials & 
      methods: PubMed was used as an electronic database, and a total of 29 articles 
      were reviewed which reported dermatological AEs following combination therapies 
      with nivolumab, ipilimumab, axitinib, pembrolizumab, lenvatinib, avelumab, 
      atezolizumab, carboplatin, etoposide, paclitaxel, bevacizumab, pemetrexed, 
      cisplatin and durvalumab. Results: The dermatological AEs reported were mutually 
      inclusive and the highest incidence of specific AEs was seen in the following 
      combinations: rash in the nivolumab/ipilimumab and lenvatinib/pembrolizumab 
      combinations, pruritus in the atezolizumab/nab-paclitaxel combination, dry skin 
      and palmar-plantar erythrodysesthesia in the axitinib/pembrolizumab combination, 
      and alopecia and severe skin reactions in the 
      pembrolizumab/carboplatin/paclitaxel combination. Conclusion: Knowledge of such 
      side effects is of benefit when choosing an optimal treatment regimen and should 
      be integrated into the monitoring and follow-up phases of treatment.
FAU - Salloum, Antoine
AU  - Salloum A
AUID- ORCID: 0000-0002-7184-9859
AD  - Department of Internal Medicine, Roger Williams Medical Center, RI, USA.
AD  - Dermatologic SurgiCenter, Philadelphia, PA, USA.
FAU - Habre, Maya
AU  - Habre M
AD  - Faculty of Medicine, University of Balamand, Beirut, Lebanon.
AD  - Department of Dermatology, Saint Georges Hospital University Medical Center, 
      Beirut, Lebanon.
FAU - Chebl, Joanna Abi
AU  - Chebl JA
AD  - Faculty of Medicine, University of Balamand, Beirut, Lebanon.
FAU - Chebl, Karen Abi
AU  - Chebl KA
AD  - Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Atallah, Carl
AU  - Atallah C
AD  - University of Balamand Faculty of Medicine & Medical Sciences El-Koura, Lebanon.
FAU - Medawar, Georgio
AU  - Medawar G
AUID- ORCID: 0000-0001-9327-194X
AD  - Department of Internal Medicine, Roger Williams Medical Center, RI, USA.
FAU - Kourie, Hampig R
AU  - Kourie HR
AD  - Department of Hematology-Oncology, Oncology department, Hotel Dieu de France 
      Hospital, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20220302
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
RN  - BG3F62OND5 (Carboplatin)
RN  - C9LVQ0YUXG (Axitinib)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Axitinib
MH  - Carboplatin
MH  - Humans
MH  - *Immune Checkpoint Inhibitors
MH  - Ipilimumab
MH  - *Nivolumab/therapeutic use
MH  - Paclitaxel
OTO - NOTNLM
OT  - adverse events
OT  - chemotherapy
OT  - combination therapy
OT  - dermatological
OT  - immune checkpoint inhibitors
OT  - immunotherapy
OT  - rash
OT  - side effects
OT  - targeted therapy
EDAT- 2022/03/03 06:00
MHDA- 2022/05/06 06:00
CRDT- 2022/03/02 05:44
PHST- 2022/03/03 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/03/02 05:44 [entrez]
AID - 10.2217/imt-2021-0244 [doi]
PST - ppublish
SO  - Immunotherapy. 2022 Apr;14(6):489-503. doi: 10.2217/imt-2021-0244. Epub 2022 Mar 
      2.